Effects of two mesenchymal cell populations on hepatocytes and lymphocytes

Liver Transplantation

Volumn 18, Issue 11, 2012, Pages 1384-1394

  Gómez Aristizábal, Alejandro ^a   Ng, Corey ^a   Ng, Joseph ^a   Davies, John E ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYTOCHROME P450; INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA; PHYTOHEMAGGLUTININ; PROGRAMMED DEATH 1 LIGAND 1; SCATTER FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; LYMPHOCYTE; MALE; MESENCHYMAL STROMA CELL; NONHUMAN; PERICYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UMBILICAL CORD; UMBILICAL CORD PERIVASCULAR CELL; UREA CYCLE;

ANIMALS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; INFLAMMATION; INTERFERON-GAMMA; LYMPHOCYTES; MALE; MESENCHYMAL STROMAL CELLS; MICROSCOPY, FLUORESCENCE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RATS; RATS, WISTAR; UMBILICAL CORD;

EID: 84868114227     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23500     Document Type: Article

References (55)

1. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH,. Acute liver failure: summary of a workshop. Hepatology 2008; 47: 1401-1415.
2. Statistics Canada. Age-standardized mortality rates by selected causes, by sex. http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health30a- eng.htm. Accessed August 2011.
3. ClÃria J, López-Parra M, Titos E, GonzÂlez- Périz A,. The role of inflammatory mediators in liver failure. In:, Ginès P, Kamath PS, Arroyo V, eds. Chronic Liver Failure: Mechanisms and Management (Clinical Gastroenterology). 1st ed. New York, NY: Humana Press; 2011: 131-154.
4. Pulavendran S, Vignesh J, Rose C,. Differential anti-inflammatory and anti-fibrotic activity of transplanted mesenchymal vs. hematopoietic stem cells in carbon tetrachloride-induced liver injury in mice. Int Immunopharmacol 2010; 10: 513-519.
5. Markiewski MM, DeAngelis RA, Lambris JD,. Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiologic processes? Mol Immunol 2006; 43: 45-56.
6. Michalopoulos GK, DeFrances MC,. Liver regeneration. Science 1997; 276: 60-66.
7. Drixler TA, Vogten MJ, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE, Borel Rinkes IH,. Liver regeneration is an angiogenesis-associated phenomenon. Ann Surg 2002; 236: 703-711.
8. Ito H, Hoshi M, Ohtaki H, Taguchi A, Ando K, Ishikawa T, et al. Ability of IDO to attenuate liver injury in alpha-galactosylceramide-induced hepatitis model. J Immunol 2010; 185: 4554-4560.
9. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI,. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009; 20: 419-427.
10. Singer NG, Caplan AI,. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011; 6: 457-478.
11. Fang B, Song Y, Lin Q, Zhang Y, Cao Y, Zhao RC, Ma Y,. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant 2007; 11: 814-817.
12. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G,. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-1490.
13. Yoo KH, Jang IK, Lee MW, Kim HE, Yang MS, Eom Y, et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 2009; 259: 150-156.
14. Ennis J, Götherström C, Le Blanc K, Davies JE,. In vitro immunologic properties of human umbilical cord perivascular cells. Cytotherapy 2008; 10: 174-181.
15. Gómez-Aristizábal A, Keating A, Davies JE,. Mesenchymal stromal cells as supportive cells for hepatocytes. Mol Ther 2009; 17: 1504-1508.
16. Li C, Kong Y, Wang H, Wang S, Yu H, Liu X, et al. Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J Hepatol 2009; 50: 1174-1183.
17. Dalakas E, Newsome PN, Boyle S, Brown R, Pryde A, McCall S, et al. Bone marrow stem cells contribute to alcohol liver fibrosis in humans. Stem Cells Dev 2010; 19: 1417-1425.
18. Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006; 130: 1807-1821.
19. di Bonzo LV, Ferrero I, Cravanzola C, Mareschi K, Rustichell D, Novo E, et al. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 2008; 57: 223-231.
20. Sakaida I, Terai S, Nishina H, Okita K,. Development of cell therapy using autologous bone marrow cells for liver cirrhosis. Med Mol Morphol 2005; 38: 197-202.
21. Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem 2007; 40: 893-899.
22. Yagi H, Parekkadan B, Suganuma K, Soto-Gutierrez A, Tompkins RG, Tilles AW, Yarmush ML,. Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure. Tissue Eng Part A 2009; 15: 3377-3388.
23. Kharaziha P, Hellström PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatology 2009; 21: 1199-1205.
24. Tsai PC, Fu TW, Chen YM, Ko TL, Chen TH, Shih YH, et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Liver Transpl 2009; 15: 484-495.
25. Baksh D, Yao R, Tuan RS,. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007; 25: 1384-1392.
26. Sarugaser R, Hanoun L, Keating A, Stanford WL, Davies JE,. Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy. PLoS One 2009; 4: e6498.
27. Prasanna SJ, Gopalakrishnan D, Shankar SR, Vasandan AB,. Pro-inflammatory cytokines, IFNÎ and TNFα, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 2010; 5: e9016.
28. Moldéus P, Högberg J, Orrenius S,. Isolation and use of liver cells. Methods Enzymol 1978; 52: 60-71.
29. Kreamer BL, Staecker JL, Sawada N, Sattler GL, Hsia MT, Pitot HC,. Use of a low-speed, iso-density Percoll centrifugation method to increase the viability of isolated rat hepatocyte preparations. In Vitro Cell Dev Biol 1986; 22: 201-211.
30. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
31. Ennis J, Sarugaser R, Gomez A, Baksh D, Davies JE,. Isolation, characterization, and differentiation of human umbilical cord perivascular cells (HUCPVCs). Methods Cell Biol 2008; 86: 121-136.
32. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE,. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 2005; 23: 220-229.
33. Raman D, Sobolik-Delmaire T, Richmond A,. Chemokines in health and disease. Exp Cell Res 2011; 317: 575-589.
34. Tipnis S, Viswanathan C, Majumdar AS,. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol 2010; 88: 795-806.
35. Wagner W, Feldmann RE Jr, Seckinger A, Maurer MH, Wein F, Blake J, et al. The heterogeneity of human mesenchymal stem cell preparations-evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol 2006; 34: 536-548.
36. Keating A,. How do mesenchymal stromal cells suppress T cells? Cell Stem Cell 2008; 2: 106-108.
37. Rosmorduc O, Housset C,. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30: 258-270.
38. Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R,. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-1195.
39. Nomura M, Yamagishi S, Harada S, Hayashi Y, Yamashima T, Yamashita J, Yamamoto H,. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995; 270: 28316-28324.
40. Shibuya M,. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001; 33: 409-420.
41. Fischer C, Mazzone M, Jonckx B, Carmeliet P,. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008; 8: 942-956.
42. Deleve LD, Wang X, Guo Y,. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008; 48: 920-930.
43. Bhatia SN, Balis UJ, Yarmush ML, Toner M,. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J 1999; 13: 1883-1900.
44. Higashiyama S, Noda M, Muraoka S, Uyama N, Kawada N, Ide T, et al. Maintenance of hepatocyte functions in coculture with hepatic stellate cells. Biochem Eng J 2004; 20: 113-118.
45. Morin O, Normand C,. Long-term maintenance of hepatocyte functional activity in co-culture: requirements for sinusoidal endothelial cells and dexamethasone. J Cell Physiol 1986; 129: 103-110.
46. O'Grady JG,. Acute liver failure. Postgrad Med J 2005; 81: 148-154.
47. Khetani SR, Szulgit G, Del Rio JA, Barlow C, Bhatia SN,. Exploring interactions between rat hepatocytes and nonparenchymal cells using gene expression profiling. Hepatology 2004; 40: 545-554.
48. Opal SM, DePalo VA,. Anti-inflammatory cytokines. Chest 2000; 117: 1162-1172.
49. Nasef A, Ashammakhi N, Fouillard L,. Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med 2008; 3: 531-546.
50. Jin Y, Chauhan SK, El Annan J, Sage PT, Sharpe AH, Dana R,. A novel function for programmed death ligand-1 regulation of angiogenesis. Am J Pathol 2011; 178: 1922-1929.
51. Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L,. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 2009; 182: 7509-7517.
52. Kassel R, Cruise MW, Iezzoni JC, Taylor NA, Pruett TL, Hahn YS,. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology 2009; 50: 1625-1637.
53. Mataki N, Kikuchi K, Kawai T, Higashiyama M, Okada Y, Kurihara C, et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases. Am J Gastroenterol 2007; 102: 302-312.
54. Carvalho AB, Quintanilha LF, Dias JV, Paredes BD, Mannheimer EG, Carvalho FG, et al. Bone marrow multipotent mesenchymal stromal cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury. Stem Cells 2008; 26: 1307-1314.
55. Asahina K, Tsai SY, Li P, Ishii M, Maxson RE Jr, Sucov HM, Tsukamoto H,. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology 2009; 49: 998-1011.